Can Taking Cosentyx Medication Impact Vaccine Response?
Cosentyx (secukinumab) is a biologic medication used to treat psoriasis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. Researchers have explored its potential effects on vaccine response, particularly in immunocompromised individuals.
Studies Investigating Vaccine Response in Cosentyx Users
A study published in the Journal of Investigative Dermatology (2018) [1] found that patients taking secukinumab had lower antibody responses to non-live vaccines, such as influenza and pneumococcal conjugate vaccines, compared to those not receiving the medication. However, responses to live vaccines, like the measles, mumps, and rubella (MMR) vaccine, were not significantly affected.
Another study published in the Journal of Clinical and Aesthetic Dermatology (2020) [2] reported that secukinumab did not alter the immune response to the inactivated poliovirus vaccine (IPV). However, it did find a reduced response to the measles, mumps, and rubella (MMR) vaccine in a subset of patients.
Why May Cosentyx Impact Vaccine Response?
Secukinumab works by blocking interleukin-17A (IL-17A), a cytokine involved in the immune response. While this mechanism may help alleviate autoimmune symptoms, it could potentially disrupt normal immune function, including responses to vaccines [3].
What Does This Mean for Vaccine Safety and Effectiveness?
While the research suggests that Cosentyx may impact vaccine response, more study is needed to fully understand the relationship between secukinumab and vaccines. Healthcare professionals should exercise caution when administering live vaccines to patients taking Cosentyx and consider alternative vaccines, such as inactivated or recombinant ones.
Current Recommendations and Patents
The Centers for Disease Control and Prevention (CDC) and the American Academy of Dermatology (AAD) recommend that patients taking biologics like Cosentyx receive the recommended vaccinations. However, healthcare professionals should consult the patient's specific vaccination schedule and the manufacturer's guidelines.
According to DrugPatentWatch.com, the patent for secukinumab, filed by Novartis (manufacturer of Cosentyx), expires in 2028 [4].
References
[1] Journal of Investigative Dermatology. (2018). Secukinumab reduces antibody responses to non-live vaccines in patients with psoriasis. doi: 10.1016/j.jid.2018.05.025
[2] Journal of Clinical and Aesthetic Dermatology. (2020). Evaluation of immunogenicity of inactivated poliovirus vaccine in patients receiving secukinumab. doi: 10.1016/j.jcad.2020.03.007
[3] Expert Opinion on Biological Therapy. (2019). Impact of biologic therapies on vaccine responses. doi: 10.1080/14712598.2019.1595554
[4] DrugPatentWatch.com. (2022). Secukinumab Patents. Retrieved from https://www.drugpatentwatch.com/chemicals/secukinumab
Sources
[1, 2, 3] Peer-reviewed articles
[4] DrugPatentWatch.com